Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ionis Pharmaceuticals, Inc.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to host 2025 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis reports first quarter 2025 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis reports fourth quarter and full year 2024 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Ionis to hold fourth quarter and full year 2024 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Tickers IONS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.